Interleukin-6 - A key regulator of colorectal cancer development

International Journal of Biological Sciences

Volumn 8, Issue 9, 2012, Pages 1248-1253

  Waldner, Maximilian J ^a   Foersch, Sebastian ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Colorectal cancer; IL 6; Interleukin 6

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; BIOLOGICAL MODEL; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84869758362     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4614     Document Type: Review

References (46)

1. Rous P, Beard JW. The Progression to Carcinoma of Virus-Induced Rabbit Papillomas (Shope). J Exp Med. 1935; 62: 523-548.
2. Pitot HC. The molecular biology of carcinogenesis. Cancer. 1993; 72: 962-970.
3. Foulds L. The natural history of cancer. J Chronic Dis. 1958; 8: 2-37.
4. Foulds L. The experimental study of tumor progression: a review. Cancer Res. 1954; 14: 327-339.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525-532.
6. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010; 375: 1030-1047.
7. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140: 1807-1816.
8. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004; 14: 433-439.
9. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998; 16: 249-284.
10. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002; 39: 531-536.
11. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011; 22: 83-89.
12. Kishimoto T. The biology of interleukin-6. Blood. 1989; 74: 1-10.
13. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14: 109-119.
14. Yamamoto K, Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther. 2012; 91: 574-576.
15. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer - more than a gut feeling? Cell Div. 2010; 5: 14.
16. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9: 798-809.
17. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992; 258: 593-597.
18. Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K, Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998; 22: 895-898.
19. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83: 222-226.
20. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 2002; 102: 169-178.
21. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis. 2010; 25: 135-140.
22. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000; 7: 133-138.
23. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007; 96: 474-476.
24. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535.
25. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006; 23: 1097-1104.
26. Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 2008; 1: 175-182.
27. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6: 583-588.
28. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005; 7: 545-555.
29. Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, Fischer JR, Lorenzoni M, Givel JC, et al. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer. 1992; 28A: 1894-1899.
30. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004; 21: 491-501.
31. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15: 103-113.
32. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15: 91-102.
33. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene. 2007; 26: 4833-4841.
34. Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med. 2010; 207: 2855-2868.
35. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121: 3375-3383.
36. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995; 86: 685-691.
37. Racadot E, Audhuy B, Duvernoy H, Thyss A, Lang JM, Wijdenes J, et al. Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody. Cytokines Mol Ther. 1995; 1: 133-138.
38. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol. 1994; 98: 323-329.
39. Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010; 103: 1154-1162.
40. Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010; 16: 5759-5769.
41. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011; 71: 1455-1465.
42. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993; 53: 851-856.
43. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012; 52: 199-219.
44. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood. 2012; 119(20):4614-4618.
45. Seavey MM, Lu LD, Stump KL, Wallace NH, Hockeimer W, O'Kane TM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012; 11: 984-993.
46. Waetzig GH, Rose-John S. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets. 2012; 16: 225-236.